Long‐term safety and tolerability of lacosamide monotherapy in patients with epilepsy: Results from a multicenter, open‐label trial
Abstract The primary objective of this trial (SP1042; NCT02582866) was to assess long‐term safety and tolerability of lacosamide monotherapy (200‐600 mg/day) in adults with focal (partial‐onset) seizures or generalized tonic‐clonic seizures (without clear focal origin). This Phase III, long‐term, op...
Main Authors: | Elinor Ben‐Menachem, Jacqueline Dominguez, József Szász, Cynthia Beller, Charles Howerton, Lori Jensen, Carrie McClung, Robert Roebling, Björn Steiniger‐Brach |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-09-01
|
Series: | Epilepsia Open |
Subjects: | |
Online Access: | https://doi.org/10.1002/epi4.12522 |
Similar Items
-
Safety and tolerability of short‐term infusions of intravenous lacosamide in pediatric patients with epilepsy: An open‐label, phase 2/3 trial
by: Mark Kristof Farkas, et al.
Published: (2023-03-01) -
The Effect of Lacosamide Polytherapy on Seizure Prognosis in Focal Epilepsies
by: Mehmet Taylan PEKÖZ, et al.
Published: (2021-09-01) -
Clinical Analysis of Lacosamide Monotherapy in the Treatment of Self-Limited Epilepsy with Centrotemporal Spikes
by: Feng J, et al.
Published: (2024-03-01) -
The Role of Add-On Lacosamide Therapy in the Treatment of Focal Onset Epilepsy
by: Güray KOÇ, et al.
Published: (2017-12-01) -
Genomic and clinical predictors of lacosamide response in refractory epilepsies
by: Sinéad B. Heavin, et al.
Published: (2019-12-01)